GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (HKSE:01093) » Definitions » Debt-to-Asset

CSPC Pharmaceutical Group (HKSE:01093) Debt-to-Asset : 0.02 (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is CSPC Pharmaceutical Group Debt-to-Asset?

CSPC Pharmaceutical Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$656 Mil. CSPC Pharmaceutical Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$117 Mil. CSPC Pharmaceutical Group's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was HK$50,622 Mil. CSPC Pharmaceutical Group's debt to asset for the quarter that ended in Dec. 2023 was 0.02.


CSPC Pharmaceutical Group Debt-to-Asset Historical Data

The historical data trend for CSPC Pharmaceutical Group's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSPC Pharmaceutical Group Debt-to-Asset Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 - 0.01 0.02

CSPC Pharmaceutical Group Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - 0.01 - 0.02

Competitive Comparison of CSPC Pharmaceutical Group's Debt-to-Asset

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSPC Pharmaceutical Group's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's Debt-to-Asset falls into.



CSPC Pharmaceutical Group Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

CSPC Pharmaceutical Group's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(656.096 + 117.098) / 50622.46
=0.02

CSPC Pharmaceutical Group's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(656.096 + 117.098) / 50622.46
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CSPC Pharmaceutical Group  (HKSE:01093) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


CSPC Pharmaceutical Group Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of CSPC Pharmaceutical Group's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CSPC Pharmaceutical Group (HKSE:01093) Business Description

Traded in Other Exchanges
Address
No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.

CSPC Pharmaceutical Group (HKSE:01093) Headlines

No Headlines